{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:18:03Z","timestamp":1787026683838,"version":"build-2736575974"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.00212","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T04:29:25Z","timestamp":1590121765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["An Update in Drug-Induced Thrombotic Microangiopathy"],"prefix":"10.3389","volume":"7","author":[{"given":"Thomas","family":"Chatzikonstantinou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriilaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilles","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gavriilaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.blre.2019.03.003","article-title":"Hypertension in hematologic malignancies and hematopoietic cell transplantation: an emerging issue with the introduction of novel treatments","volume":"35","author":"Gavriilaki","year":"2019","journal-title":"Blood Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"E241","DOI":"10.1002\/ajh.25208","article-title":"Drug-induced thrombotic microangiopathy: an updated systematic review, 2014-2018","volume":"93","author":"Saleem","year":"2018","journal-title":"Am J Hematol"},{"key":"B4","article-title":"Transplant-associated thrombotic microangiopathy is independently associated with ruxolitinib administration in patients with graft-versus-host-disease","author":"Gavriilaki","year":"2020","journal-title":"EBMT"},{"key":"B5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/j.ajkd.2019.09.011","article-title":"Chronic Microangiopathy Due to DCR-MYC, a Myc-Targeted Short Interfering RNA","volume":"75","author":"Miller","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4327904","DOI":"10.1155\/2018\/4327904","article-title":"Thrombotic thrombocytopenic purpura associated with pazopanib","volume":"2018","author":"Syed","year":"2018","journal-title":"Case Rep Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1053\/j.ajkd.2018.09.013","article-title":"Acute thrombotic microangiopathy and cortical necrosis following administration of Alemtuzumab: a case report","volume":"73","author":"Liou","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"886","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00009","article-title":"Drug-induced thrombocytopenia: a systematic review of published case reports","volume":"129","author":"George","year":"1998","journal-title":"Ann Internal Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the oklahoma registry and the bloodcenter of wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4997\/JRCPE.2018.206","article-title":"Drug induced thrombotic microangiopathy caused by levofloxacin","volume":"48","author":"Kazi","year":"2018","journal-title":"J R College Phys Edinburgh"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2016-05-715987","article-title":"Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature","volume":"128","author":"Kavanagh","year":"2016","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2016-08-736579","article-title":"A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER","volume":"129","author":"Hunt","year":"2017","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40425-017-0224-7","article-title":"Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)","volume":"5","author":"King","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/imj.12055","article-title":"Thrombotic thrombocytopenic purpura associated with adalimumab (Humira) treatment in Crohn disease","volume":"43","author":"Zbaras","year":"2013","journal-title":"Internal Med J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/RHU.0000000000000684","article-title":"Development of thrombotic thrombocytopenic purpura in association with the monoclonal antibody, golimumab, used to treat rheumatoid arthritis, in a case with literature review","volume":"24","author":"Cepeda","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol Dialysis Transpl"},{"key":"B20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1517\/14740330902942299","article-title":"Thrombotic microangiopathy associated with gemcitabine: rare but real","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"B21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/1097-0142(19850101)55:1<51::AID-CNCR2820550109>3.0.CO;2-D","article-title":"Renal failure and hemolytic anemia associated with mitomycin C. A case report","volume":"55","author":"Price","year":"1985","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000495031","article-title":"Treatment of chemotherapy-induced thrombotic microangiopathy with eculizumab in a patient with metastatic breast cancer","volume":"12","author":"Hausberg","year":"2019","journal-title":"Case Rep Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1179\/1973947813Y.0000000122","article-title":"Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series","volume":"26","author":"Leal","year":"2014","journal-title":"J Chemother"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e3088","DOI":"10.7759\/cureus.3088","article-title":"Drug-induced thrombotic microangiopathy caused by gemcitabine","volume":"10","author":"Hasan","year":"2018","journal-title":"Cureus"},{"key":"B25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet","year":"2019","journal-title":"Br J Clin Pharm"},{"key":"B26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5414\/CN108838","article-title":"Gemcitabine-induced hemolytic-uremic syndrome treated with eculizumab or plasmapheresis: two case reports","volume":"87","author":"Lopez Rubio","year":"2017","journal-title":"Clin Nephrol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.1985.3.5.723","article-title":"Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy","volume":"3","author":"Cantrell","year":"1985","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","article-title":"Gemcitabine-associated thrombotic thrombocytopenic purpura","volume":"8","author":"Zupancic","year":"2007","journal-title":"Lancet. Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/(SICI)1096-8652(199908)61:4<268::AID-AJH9>3.0.CO;2-O","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): a case report","volume":"61","author":"Leach","year":"1999","journal-title":"Am J Hematol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/00043426-200009000-00024","article-title":"Hemolytic uremic syndrome secondary to the treatment of acute lymphoblastic leukemia","volume":"22","author":"Kanchi","year":"2000","journal-title":"J Pediatr Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1097\/MJT.0b013e3181cea0b3","article-title":"Docetaxel-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome-related complex in a patient with metastatic prostate cancer?","volume":"18","author":"Shrestha","year":"2011","journal-title":"Am J Therap"},{"key":"B32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3109\/0284186X.2012.661073","article-title":"Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma","volume":"51","author":"Crouzet","year":"2012","journal-title":"Acta Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/ki.2013.408","article-title":"Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer","volume":"85","author":"Shavit","year":"2014","journal-title":"Kidney Internat"},{"key":"B34","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/MPH.0000000000000987","article-title":"Recurrent atypical hemolytic uremic syndrome in children with acute lymphoblastic leukemia undergoing maintenance chemotherapy","volume":"40","author":"Cheng","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/MPH.0000000000001050","article-title":"Thrombotic thrombocytopenic purpura in a child treated for acute lymphoblastic leukemia: case report and review of literature","volume":"40","author":"De Leonardis","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.3892\/ol.2015.3338","article-title":"Thrombotic thrombocytopenic purpura following salvage chemotherapy with paclitaxel, ifosfamide and cisplatin in a patient with a refractory germ cell tumor: a case report and review of the literature","volume":"10","author":"Ulas","year":"2015","journal-title":"Oncol Lett"},{"key":"B37","doi-asserted-by":"publisher","first-page":"439","DOI":"10.21873\/invivo.11080","article-title":"Thrombotic microangiopathy following chemotherapy with s-1 and cisplatin in a patient with gastric cancer: a case report","volume":"31","author":"Muto","year":"2017","journal-title":"In vivo"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41409-018-0159-8","article-title":"High-dose Carboplatin\/Etoposide\/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma","volume":"53","author":"Jodele","year":"2018","journal-title":"Bone Marrow Transpl"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/cncr.28547","article-title":"Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation","volume":"120","author":"Tseng","year":"2014","journal-title":"Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e17148","DOI":"10.1097\/MD.0000000000017148","article-title":"Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: a renal biopsy and autopsy case report","volume":"98","author":"Cassol","year":"2019","journal-title":"Medicine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"E53","DOI":"10.1002\/ajh.24662","article-title":"Ixazomib-induced thrombotic microangiopathy","volume":"92","author":"Yui","year":"2017","journal-title":"Am J Hematol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"7063145","DOI":"10.1155\/2018\/7063145","article-title":"Drug-induced thrombotic microangiopathy due to cumulative toxicity of ixazomib","volume":"2018","author":"Atallah-Yunes","year":"2018","journal-title":"Case Rep Hematol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1097\/HS9.0000000000000192","article-title":"Drug-induced thrombotic microangiopathy during maintenance treatment in a patient with multiple myeloma","volume":"3","author":"Higuero Saavedra","year":"2019","journal-title":"Hemasphere"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/ccr3.1214","article-title":"Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment","volume":"5","author":"Gosain","year":"2017","journal-title":"Clin Case Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1182\/bloodadvances.2018027532","article-title":"Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion","volume":"2","author":"Portuguese","year":"2018","journal-title":"Blood Adv"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"New Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma","volume":"8","author":"Frangie","year":"2007","journal-title":"Lancet. Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/nep.13072","article-title":"Renal thrombotic microangiopathy caused by bevacizumab","volume":"23","author":"Horino","year":"2018","journal-title":"Nephrology. (Carlton)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00467-016-3355-z","article-title":"Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome","volume":"31","author":"Yilmaz","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1177\/1078155218774895","article-title":"Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab","volume":"25","author":"Vakiti","year":"2019","journal-title":"J Oncol Pharm Practice"},{"key":"B51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12882-018-1194-9","article-title":"Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report","volume":"20","author":"Yamada","year":"2019","journal-title":"BMC Nephrol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5414\/CN108901","article-title":"Thrombotic microangiopathy associated with cetuximab, an epidermal growth factor receptor inhibitor","volume":"87","author":"Koizumi","year":"2017","journal-title":"Clin Nephrol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/0973-1482.172575","article-title":"Sunitinib-induced thrombotic microangiopathy","volume":"12","author":"Noronha","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1093\/annonc\/mdm454","article-title":"Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome","volume":"18","author":"Kapiteijn","year":"2007","journal-title":"Ann Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/1078155214568580","article-title":"Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate","volume":"22","author":"Ojeda-Uribe","year":"2016","journal-title":"J Oncol Pharm Practice"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.clbc.2017.10.001","article-title":"Palbociclib-induced thrombotic microangiopathy in metastatic breast cancer patient surviving for 18 years: case report and review of the literature","volume":"18","author":"Raiss","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/bmt.2017.39","article-title":"Transplant-associated thrombotic microangiopathy: opening Pandora's box","volume":"52","author":"Gavriilaki","year":"2017","journal-title":"Bone Marrow Transpl"},{"key":"B58","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0272-6386(89)80032-0","article-title":"Renal vascular and thrombotic effects of cyclosporine","volume":"13","author":"Remuzzi","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000504523","article-title":"Kidney disease after allogeneic hematopoietic cell transplantation: in search of the truth","volume":"2019","author":"Gavriilaki","year":"2019","journal-title":"Acta Haematol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.transproceed.2014.07.062","article-title":"Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation","volume":"46","author":"Nava","year":"2014","journal-title":"Transpl Proceed"},{"key":"B61","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1177\/1060028015593369","article-title":"Transplantation-associated thrombotic microangiopathy in patients treated with sirolimus and cyclosporine as salvage therapy for graft-versus-host disease","volume":"49","author":"Garcia-Martin","year":"2015","journal-title":"Ann Pharm"},{"key":"B62","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis","volume":"19","author":"Shayani","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"key":"B63","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dialysis Transpl"},{"key":"B64","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic microangiopathies: unraveling ariadne's thread into the labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/ndt\/9.8.1191","article-title":"Haemolytic uraemic syndrome in a renal transplant recipient during OKT3 therapy","volume":"9","author":"Dussol","year":"1994","journal-title":"Nephrol Dialy Transpl"},{"key":"B66","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"398","DOI":"10.4274\/balkanmedj.2017.1224","article-title":"Drug induced thrombotic microangiopathy with certolizumab pegol","volume":"35","author":"Baysal","year":"2018","journal-title":"Balkan Med J"},{"key":"B68","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2340\/00015555-1987","article-title":"Fatal thrombotic thrombocytopenic purpura in a psoriasis patient treated with ustekinumab and methotrexate","volume":"95","author":"Philippe","year":"2015","journal-title":"Acta Dermat Venereol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1182\/blood-2017-02-749101","article-title":"Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia","volume":"130","author":"Wayne","year":"2017","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1016\/S0272-6386(00)70321-0","article-title":"Cocaine-induced acute renal failure, hemolysis, and thrombocytopenia mimicking thrombotic thrombocytopenic purpura","volume":"35","author":"Volcy","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"B71","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jca.21687","article-title":"A case off TTP temporally associated with cocaine use: implications for treatment of suspected DITMA","volume":"34","author":"Regner","year":"2019","journal-title":"J Clin Apheresis"},{"key":"B72","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4103\/0972-5229.154561","article-title":"Thrombotic thrombocytopenic purpura and focal segmental glomerulosclerosis associated with the use of ecstasy","volume":"19","author":"Kayar","year":"2015","journal-title":"Indian J Crit Care Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","article-title":"The global burden of neurological disorders: translating evidence into policy","volume":"19","author":"Feigin","year":"2019","journal-title":"Lancet. Neurol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1212\/WNL.0000000000003691","article-title":"Expanding medicines for neurologic disorders on the WHO model list","volume":"88","author":"Rimmer","year":"2017","journal-title":"Neurology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40263-018-0488-6","article-title":"Efficacy and safety of the newer multiple sclerosis drugs approved since 2010","volume":"32","author":"Faissner","year":"2018","journal-title":"CNS Drugs"},{"key":"B76","first-page":"ECR05","article-title":"Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath 1H) or fludarabine","volume":"90","author":"Osborne","year":"2005","journal-title":"Haematologica"},{"key":"B77","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/HYPERTENSIONAHA.117.10655","article-title":"Multiple sclerosis drug fingolimod induces thrombotic microangiopathy in deoxycorticosterone acetate\/salt hypertension","volume":"72","author":"Iwazu","year":"2018","journal-title":"Hypertension"},{"key":"B78","doi-asserted-by":"publisher","first-page":"A15","DOI":"10.1136\/jnnp-2018-ANZAN.34","article-title":"035 Interferon beta induced thrombotic microangiopathy in multiple sclerosis: a clinical-pathological report","volume":"89","author":"Yam","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B79","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2169\/internalmedicine.9326-17","article-title":"Thrombotic Microangiopathy Presenting with Intestinal Involvement Following Long-term Interferon-beta1b Treatment for Multiple Sclerosis","volume":"57","author":"Omoto","year":"2018","journal-title":"Internal Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/ckj\/sfw143","article-title":"Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab","volume":"10","author":"Allinovi","year":"2017","journal-title":"Clin Kidney J"},{"key":"B81","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1053\/j.ajkd.2017.05.023","article-title":"Quinine-induced thrombotic microangiopathy: a report of 19 patients","volume":"70","author":"Page","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/jppr.1248","article-title":"Suspected hydroxychloroquine-induced thrombotic thrombocytopaenic purpura","volume":"48","author":"Fromm","year":"2017","journal-title":"J Pharm Practice Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000496325","article-title":"A novel association between antiretroviral therapy and drug-induced immune thrombocytopenia purpura","volume":"141","author":"Howard","year":"2019","journal-title":"Acta Haematol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"A109","DOI":"10.1053\/j.ajkd.2016.03.370","article-title":"Thrombotic thrombocytopenic purpura and rhabdomyolysis associated with ciprofloxacin use","volume":"67","author":"Trasar","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B85","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jca.21470","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the american society for apheresis: the seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1172\/JCI136094","article-title":"Complementopathies and precision medicine","volume":"130","author":"Gavriilaki","year":"2020","journal-title":"J Clin Invest"},{"key":"B87","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.nefroe.2018.10.016","article-title":"Onco-nephrology: cancer, chemotherapy and kidney","volume":"39","author":"de Francisco","year":"2019","journal-title":"Nefrologia"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00212\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T04:29:28Z","timestamp":1590121768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00212\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":87,"alternative-id":["10.3389\/fmed.2020.00212"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.00212","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]},"article-number":"212"}}